Optimizing Barostim Outcomes: Practical Approaches to Patient Selection and Monitoring
Cynthia J. Bither, ACNP-BC, MSN
Andrea Wallace, MSN, FNP-C, HF-Cert
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
Robert J. Mentz, MD, FHFSA, FACC, FAHA
Piotr Ponikowski, MD, PhD, FESC, FHFA
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Pam R. Taub, MD, FACC, FASPC
Jan T. Kielstein, MD, FASN, FERA
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
Stefan D. Anker, MD, PhD
Mahir Karakas, MD, PhD, MBA
Impact of Barostim on Heart Failure Hospitalization
Jacob Abraham, MD
Managing Patients With AAV in the Rheumatology Clinic
Andreas Kronbichler, MD
Bernhard Hellmich, MD
Elevating Care for Patients With Severe Renal Disease in AAV
Silke R. Brix, MD, MRCP, SCPR
Pearls of Wisdom: Optimizing Hyperkalemia Management in Patients with CKD
Matthew R. Weir, MD
Nihar Desai, MD
Ellie Kelepouris, MD, FACP, FAHA
Implementing the SOC Induction Therapies in AAV
Tailoring Treatment for Optimal Outcomes in Patients With AAV
Don't Miss It! Rapid & Accurate AAV Diagnosis
Optimizing AAV Outcomes: Maintenance Therapies
Beyond the Broadcast: Expert Insights on SGLT2 Inhibitors in Cardiometabolic Care
Melissa Magwire, RN, MSN, CDE
Matthew Bullington, PharmD
Dawn M. Denicola, FNP-C
Keith Miller, MD
Breaking the Cycle: Addressing Hyperkalemia in CKD and Heart Failure to Optimize RAASi Therapy
Mikhail Kosiborod, MD
Stephen J. Greene, MD, FACC, FHFSA
Refining Strategies for Enhancing Cardiorenal Outcomes With SGLT2 Inhibitors: Optimizing the Cardiometabolic Care Model
Pulmonary Hypertension: Diagnosis, Management, and Updates – Chairperson’s Perspective
Vallerie V. McLaughlin, MD